Matinas Biopharma (MTNB)
(Delayed Data from AMEX)
$0.18 USD
0.00 (-1.43%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $0.18 0.00 (0.61%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
MTNB 0.18 0.00(-1.43%)
Will MTNB be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for MTNB based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MTNB
Matinas Biopharma Holdings, Inc. (MTNB) Reports Q1 Loss, Tops Revenue Estimates
Matinas Biopharma Holdings, Inc. (MTNB) Reports Q3 Loss, Misses Revenue Estimates
MTNB: What are Zacks experts saying now?
Zacks Private Portfolio Services
After Plunging 20.2% in 4 Weeks, Here's Why the Trend Might Reverse for Matinas Biopharma Holdings, Inc. (MTNB)
Matinas Biopharma Holdings, Inc. (MTNB) Reports Q2 Loss, Misses Revenue Estimates
Matinas Biopharma Holdings, Inc. (MTNB) Reports Q1 Loss, Misses Revenue Estimates
Other News for MTNB
Matinas BioPharma initiated with bullish view at Alliance Global Partners, here's why
Matinas BioPharma’s Multi-Million Share Sale and Lock-Up Deal
Matinas BioPharma Prices $10 Million Registered Direct Offering
Matinas BioPharma prices $10 million registered direct offering
Matinas Biopharma prices $10 million registered direct offering